Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
0 hedge funds and large institutions have $0 invested in Clementia Pharmaceuticals Inc. in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 48 closing their positions.
100% less funds holding
Funds holding: 48 → 0 (-48)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $732M → $0 (-$732M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 48
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$272M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$97.2M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$70.7M |
| 4 |
Janus Henderson Group
London,
|
-$53.5M |
| 5 |
JP Morgan Chase
New York
|
-$41.7M |
CMTA Hedge Fund Activity: Q2 2019 in Review
0 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q2 2019, worth a combined $0 — down 100% from $732M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of CMTA and 0 opened new positions — a net loss of 48 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was OrbiMed, exiting entirely with an estimated $272M sold.
- 0 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q2 2019, down from 48 in Q1 2019.
- Funds reported $0 of Clementia Pharmaceuticals Inc. stock for Q2 2019, down 100% quarter-over-quarter.
- 0 funds opened new Clementia Pharmaceuticals Inc. positions in Q2 2019 and 48 closed out, a net change of -48 holders.
- The largest Clementia Pharmaceuticals Inc. seller in Q2 2019 was OrbiMed, an estimated $272M sold.
Based on aggregated 13F filings for Q2 2019.